Theoretical and Natural Science

- The Open Access Proceedings Series for Conferences


Theoretical and Natural Science

Vol. 21, 20 December 2023

Open Access | Article

Gastric cancer stem cell: Carcinogenesis and targeted personalized therapies of cancer stem cell

Zhou Zhuanghan * 1
1 Wenzhou-Kean University

* Author to whom correspondence should be addressed.

Theoretical and Natural Science, Vol. 21, 15-20
Published 20 December 2023. © 2023 The Author(s). Published by EWA Publishing
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citation Zhou Zhuanghan. Gastric cancer stem cell: Carcinogenesis and targeted personalized therapies of cancer stem cell. TNS (2023) Vol. 21: 15-20. DOI: 10.54254/2753-8818/21/20230801.

Abstract

Gastric cancer (GC) is one of the most common cancers in worldwide range which ranks fifth, and it is also third most common cancerous death reason. Although there has been a decline in the rate of incidence and mortality over recent fifty years, cure for GC is extremely hard to achieve. The symptoms are not conspicuous at early stage of the GC patients usually, which is the reason GC is diagnosed at terminal stage. And it is worse that the prognosis effect is outrageously bad, the median survival times are mostly less than a year. Under this condition, prevention is the most efficient method to reduce the incidence and mortality, meanwhile, the application of newly emerged therapy should be attached importance to GC. To create accurate treatment to achieve this goal, it is necessary to comprehend the mechanism of the carcinogenesis, and mechanism of cancer development, the critical transformation points derived from those mechanism will divide the different methodology applying period. This article mainly focuses on the cancer stem cell (CSC) aspect of carcinogenesis, cancer development to inform the points which can be utilized to intervene and new therapy method.

Keywords

gastric cancer, carcinogenesis, cancer stem cell (CSC), targeted personalized therapy

References

1. Shackleton, M., Quintana, E., Fearon, E. R., & Morrison, S. J. (2009). Heterogeneity in cancer: Cancer stem cells versus Clonal Evolution. Cell, 138(5), 822–829. https://doi.org/10.1016/j.cell.2009.08.017

2. Lee, G., & R Hall, R. (2016). Cancer stem cells: Cellular plasticity, niche, and its clinical relevance. Journal of Stem Cell Research & Therapy, 06(10). https://doi.org/10.4172/2157-7633.1000363

3. Brungs, D., Aghmesheh, M., Vine, K. L., Becker, T. M., Carolan, M. G., & Ranson, M. (2015). Gastric cancer stem cells: Evidence, potential markers, and clinical implications. Journal of Gastroenterology, 51(4), 313–326. https://doi.org/10.1007/s00535-015-1125-5

4. Vlashi, E., & Pajonk, F. (2015). Cancer stem cells, cancer cell plasticity and radiation therapy. Seminars in Cancer Biology, 31, 28–35. https://doi.org/10.1016/j.semcancer.2014.07.001

5. CORREA, P., & PIAZUELO, M. B. (2011). The gastric precancerous cascade. Journal of Digestive Diseases, 13(1), 2–9. https://doi.org/10.1111/j.1751-2980.2011.00550.x

6. Johnston, F. M., & Beckman, M. (2019). Updates on management of Gastric Cancer. Current Oncology Reports, 21(8). https://doi.org/10.1007/s11912-019-0820-4

7. Rugge, M., Fassan, M., & Graham, D. Y. (2015). Epidemiology of Gastric Cancer. Gastric Cancer, 23–34.Return to ref 9 in article

8. Han, J. P., Hong, S. J., & Kim, H. K. (2014). Long-term outcomes of early gastric cancer diagnosed as mixed adenocarcinoma after endoscopic submucosal dissection. JGH., 30(2), 316–320. https://doi.org/10.1111/jgh.12838.

9. Polk, D., Peek, R. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 10, 403–414 (2010). https://doi.org/10.1038/nrc2857

10. Jencks DS, Adam JD, Borum ML, Koh JM, Stephen S, Doman DB. Overview of Current Concepts in Gastric Intestinal Metaplasia and Gastric Cancer. Gastroenterol Hepatol (N Y). 2018 Feb;14(2):92-101. PMID: 29606921; PMCID: PMC5866308.

11. Kapadia, C. R. (2003). Gastric atrophy, metaplasia, and dysplasia. Journal of Clinical Gastroenterology, 36. https://doi.org/10.1097/00004836-200305001-00006

12. Raza M, Bhatt H. Atrophic Gastritis. [Updated 2022 Jul 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563275/

13. Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012 Jan;13(1):2-9. doi: 10.1111/j.1751-2980.2011.00550.x. PMID: 22188910; PMCID: PMC3404600.

14. McDonald, S. A. C., Greaves, L. C., Gutierrez–Gonzalez, L., Rodriguez–Justo, M., Deheragoda, M., Leedham, S. J., Taylor, R. W., Lee, C. Y., Preston, S. L., Lovell, M., Hunt, T., Elia, G., Oukrif, D., Harrison, R., Novelli, M. R., Mitchell, I., Stoker, D. L., Turnbull, D. M., Jankowski, J. A. Z., & Wright, N. A. (2008). Mechanisms of field cancerization in the human stomach: The expansion and spread of mutated gastric stem cells. Gastroenterology, 134(2), 500–510. https://doi.org/10.1053/j.gastro.2007.11.035

15. Jonaitis, P., Kupcinskas, L., & Kupcinskas, J. (2021). Molecular alterations in gastric intestinal metaplasia. International Journal of Molecular Sciences, 22(11), 5758. https://doi.org/10.3390/ijms22115758

16. DIXON, M. F. (2001). Prospects for intervention in gastric carcinogenesis: Reversibility of gastric atrophy and intestinal metaplasia. Gut, 49(1), 2–4. https://doi.org/10.1136/gut.49.1.2

17. Sung, J. K. (2016). Diagnosis and management of Gastric dysplasia. The Korean Journal of Internal Mdicine, 31(2), 201–209. https://doi.org/10.3904/kjim.2016.021

18. Rugge, Massimo M.D.; Correa, Pelayo M.D.; Dixon, Michael F. M.D.; Hattori, Takanori; Leandro, Gioacchino M.D.; Lewin, Klaus M.D.; Riddell, Robert H. M.D.; Sipponen, Pentii M.D.; Watanabe, Hidenobu M.D. Gastric Dysplasia: The Padova International Classification. The American Journal of Surgical Pathology 24(2):p 167-176, February 2000.

19. Srivastava, A., & Lauwers, G. Y. (2008). Gastric epithelial dysplasia: The Western Perspective. Digestive and Liver Disease, 40(8), 641–649. https://doi.org/10.1016/j.dld.2008.02.039

20. Baek, D.H., Kim, G.H., Park, D.Y. et al. Gastric epithelial dysplasia: characteristics and long-term follow-up results after endoscopic resection according to morphological categorization. BMC Gastroenterol 15, 17 (2015). https://doi.org/10.1186/s12876-015-0249-7

21. Correa, P. (2004). Is gastric cancer preventable? Gut, 53(9), 1217–1219. https://doi.org/10.1136/gut.2004.039834

22. Min J, Zhang C, Bliton RJ, Caldwell B, Caplan L, Presentation KS, Park DJ, Kong SH, Lee HS, Washington MK, Kim WH, Lau KS, Magness ST, Lee HJ, Yang HK, Goldenring JR, Choi E. Dysplastic Stem Cell Plasticity Functions as a Driving Force for Neoplastic Transformation of Precancerous Gastric Mucosa. Gastroenterology. 2022 Oct;163(4):875-890. doi: 10.1053/j.gastro.2022.06.021. Epub 2022 Jun 11. PMID: 35700772; PMCID: PMC9509466.

23. Oue, N., Sentani, K., Sakamoto, N. et al. Molecular carcinogenesis of gastric cancer: Lauren classification, mucin phenotype expression, and cancer stem cells. Int J Clin Oncol 24, 771–778 (2019). https://doi.org/10.1007/s10147-019-01443-9

24. Oue N, Sentani K, Sakamoto N, Yasui W. Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype. Cancer Sci. 2015 Aug;106(8):951-8. doi: 10.1111/cas.12706. Epub 2015 Jul 7. PMID: 26033320; PMCID: PMC4556382.

25. Ma J, Shen H, Kapesa L, Zeng S. Lauren classification and individualized chemotherapy in gastric cancer. Oncol Lett. 2016 May;11(5):2959-2964. doi: 10.3892/ol.2016.4337. Epub 2016 Mar 16. PMID: 27123046; PMCID: PMC4840723.

26. Qiu MZ, Cai MY, Zhang DS, Wang ZQ, Wang DS, Li YH, Xu RH. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med. 2013 Mar 6;11:58. doi: 10.1186/1479-5876-11-58. PMID: 23497313; PMCID: PMC3600019.

27. Stock, M., & Otto, F. (2005). Gene deregulation in Gastric Cancer. Gene, 360(1), 1–19. https://doi.org/10.1016/j.gene.2005.06.026.

28. Nobili S, Bruno L, Landini I, Napoli C, Bechi P, Tonelli F, Rubio CA, Mini E, Nesi G. Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol. 2011 Jan 21;17(3):290-9. doi: 10.3748/wjg.v17.i3.290. PMID: 21253387; PMCID: PMC3022288.

29. Correa, P. (2004). Is gastric cancer preventable? Gut, 53(9), 1217–1219. https://doi.org/10.1136/gut.2004.039834

30. Rugge, M., Fassan, M., & Graham, D. Y. (2015). Epidemiology of Gastric Cancer. Gastric Cancer, 23–34.

31. Panzini I, Gianni L, Fattori PP et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori88(1), 21–27 (2002).

32. Zeng S, Shen WH, Liu L. Senescence and cancer. Cancer Transl Med. (2018) 4:70–4. doi: 10.4103/ctm.ctm_22_18.

33. Hosoya N, Miyagawa K. Targeting DNA damage response in cancer therapy. Cancer Sci. (2014) 105:370–88. doi: 10.1111/cas.12366.

34. Ruhland MK, Coussens LM, Stewart SA. Senescence and cancer: an evolving inflammatory paradox. Biochim Biophys Acta. (2016) 1865:14–22. doi: 10.1016/j.bbcan.2015.10.001.

35. Coppé J-P, Desprez P-Y, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. (2010) 5:99–118. doi: 10.1146/annurev-pathol-121808-102144.

36. Kang T-W, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. (2011) 479:547–51. doi: 10.1038/nature10599.

37. Brungs, D., Aghmesheh, M., Vine, K.L. et al. Gastric cancer stem cells: evidence, potential markers, and clinical implications. J Gastroenterol 51, 313–326 (2016). https://doi.org/10.1007/s00535-015-1125-5.

38. Singh, S. R. (2013). Gastric cancer stem cells: A novel therapeutic target. Cancer Letters, 338(1), 110–119. https://doi.org/10.1016/j.canlet.2013.03.035

Data Availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).

Volume Title
Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
ISBN (Print)
978-1-83558-215-2
ISBN (Online)
978-1-83558-216-9
Published Date
20 December 2023
Series
Theoretical and Natural Science
ISSN (Print)
2753-8818
ISSN (Online)
2753-8826
DOI
10.54254/2753-8818/21/20230801
Copyright
20 December 2023
Open Access
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Copyright © 2023 EWA Publishing. Unless Otherwise Stated